Background: The addition of trastuzumab to preoperative chemotherapy for Her2-positive breast cancers has been shown to increase pCR rates. The purpose of this study was to evaluate the efficacy of trastuzumab in combination with dose-dense nab-paclitaxel followed by weekly vinorelbine. Methods: Patients with Stage I (>1.0 cm), II, or IIIA Her2-positive (defined as either immunohistochemical 3+ of fluorescence in situ hybridization-positive) breast cancer received nab-paclitaxel 260 mg/m 2 iv every 2 weeks for 4 cycles in combination followed by vinorelbine 25 mg/m 2 iv weekly with simultaneous trastuzumab (4 mg/kg loading dose then 2 mg/kg weekly) for 20 weeks. Tissue was collected at baseline, at optional midway biopsy, and post-therapy. Primary endpoint was pCR rate; secondary endpoints included response rate and toxicity. Cardiac evaluation was performed at baseline, after 4 cycles of nab-paclitaxel, after 12 weeks of vinorelbine and every 3 months thereafter. Results: To date, 21 of 50 planned patients have been accrued (3/2008 to 12/2009). 11 patients are evaluable for primary endpoint. Median age was 50.5 years (38-64). Median tumor size was 3.7 cm (1.5-7cm). 4 of 11 (36.4%) were clinically node-positive at study entry. Patients were accrued from a university center (54.5%), county hospital (18.2%), and community sites (27.3%). 4 patients were African American (36.4%), 7 were Caucasian (63.6%). The regimen was well-tolerated: 2 patients experienced grade 3 neuropathy, 1 patient grade 3 neutropenia, 1 patient had trastuzumab held for asymptomatic decrease in left ventricular ejection fraction. Clinical complete response rate was 72.7%. Partial response rate was 27.3%. 7 of 11 patients (63.6%) had pCR.
Introduction
The human epidermal growth factor receptor 2 (Her-2) is overexpressed in 20 to 25% of invasive breast cancers. 1 Several randomized trials in the adjuvant setting have evaluated the addition of trastuzumab to chemotherapy, and have shown improved disease-free and overall survival. 2 In the neoadjuvant setting, trastuzumab in combination with chemotherapy has been shown to increase pathologic complete response (pCR) rate. 3 pCR is often considered a surrogate marker of outcome after neoadjuvant therapy. This is based upon observation from several, large randomized clinical trials showing that achievement of a pCR predicted for a more favorable long-term outcome. 4 Optimal combination of trastuzumab and chemotherapy in neoadjuvant setting has not been determined. Cardiac toxicity is decreased when combining trastuzumab with a non-anthracycline based regimen. 5 Nab-paclitaxel is a unique albumin-bound formulation of paclitaxel that has shown improved response rate and time to progression compared to paclitaxel in the metastatic setting. 6 This study evaluates the novel combination of trastuzumab with dosedense nab-paclitaxel followed by weekly vinorelbine. 
Conclusions
• The combination of trastuzumab with dose-dense nab-paclitaxel is well tolerated. Main toxicities observed were fatigue and neuropathy. Two patients had trastuzumab held for asymptomatic drop in ejection fraction.
• pCR rate of 52.4% is higher than previously reported with nonanthracycline based chemotherapy in combination with trastuzumab.
• Additional evaluation of residual cancer burden planned. 
